Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959097 · ClinicalTrials.gov registry record
RB Liquid Biopsy Biorepository
A clinical trial of Retinoblastoma and Retinoblastoma Bilateral, sponsored by Children's Hospital Los Angeles.
- Recruiting
- Registry status
- 800
- Enrollment target
- 1
- Study location
NCT04959097: Recruiting study of Retinoblastoma and Retinoblastoma Bilateral, sponsored by Children's Hospital Los Angeles.
NCT04959097 is a study of Retinoblastoma and Retinoblastoma Bilateral that is actively recruiting participants, run by Children's Hospital Los Angeles. The registered enrollment target is 800 participants, above the 539-participant average among 15 other Retinoblastoma trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04959097, a study of Retinoblastoma and Retinoblastoma Bilateral, is actively recruiting participants, sponsored by Children's Hospital Los Angeles.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed. Given this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.
Primary Outcome
We aim to evaluate whether any identifiable molecular biomarkers (e.g. chromosomal alterations or tumor fraction) in the aqueous or blood can predict ocular salvage, or the likelihood of saving the eye with therapy
Conditions Studied
Study Locations (1)
California
- Children's Hospital Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2030-12-31 |
What NCT04959097 shows while recruiting
NCT04959097 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 539-participant average among 15 other Retinoblastoma trials with a reported enrollment target (48% higher).
The record links to 3 conditions, with Retinoblastoma appearing as the primary indexed condition, and to 0 interventions.
NCT04959097 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04959097 about?
NCT04959097 is a clinical study titled "RB Liquid Biopsy Biorepository". Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed. Given this limitation, we use aqueous humor (AH), the clear fluid in the front o...
What is the current status of trial NCT04959097?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2017-01-01. Estimated completion is 2030-12-31.
What conditions does trial NCT04959097 study?
This clinical trial studies the following conditions: Retinoblastoma, Retinoblastoma Bilateral, Retinoblastoma Unilateral.
Who is sponsoring clinical trial NCT04959097?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04959097 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinoblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04959097's enrollment target sits among peer trials
800 3rd of 15 higher than 13 of 15 other Retinoblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinoblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
-
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
RECRUITING
-
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
RECRUITING
-
Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
RECRUITING
-
Retinoblastoma Phase II Expanded Access Clinical Trial
RECRUITING · Phase 2
-
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI